Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 12Nausea 12Neoplasms 8Hematologic Neoplasms 5Anorexia 4Cachexia 3Breast Neoplasms 3Weight Loss 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Multiple Myeloma 2Lung Neoplasms 2Advanced Cancer 2Testicular Neoplasms 1Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy 1Sedentary Behavior 1Radiation Injuries 1Prosthesis Failure 1Postoperative Nausea and Vomiting 1Pain 1Opioid-Related Disorders 1Nutrition Disorders 1Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1Muscular Atrophy 1Multiple Endocrine Neoplasia Type 1 1Lymphoma 1Insulin Resistance 1Hyperlipidemias 1Hyperglycemia 1

Interventions

Dexmedetomidine 5Saline Solution 4Haloperidol 4Sodium Chloride 3Propofol 2Lorazepam 2suvorexant 1remimazolam 1haloperidol decanoate 1flurbiprofen axetil 1dexamethasone 21-phosphate 1Vitamin E 1Surveys and Questionnaires 1Standard of Care 1Sevoflurane 1Practice Guidelines as Topic 1Olanzapine 1Midazolam 1Melatonin 1Interviews as Topic 1Injections 1Inhalation 1Ibuprofen 1Donepezil 1Dexamethasone 1Chlorpromazine 1Anesthesia, Spinal 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Delirium × Olanzapine × Clear all
NCT01539733 2017-04-07

Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer

Amsterdam UMC, location VUmc

Phase NA Completed
101 enrolled

Delirium

Data powered by HemOnc (CC BY 4.0) Colophon âš¡